Portal and peripheral cortisol levels in obese humans
- PMID: 15095041
- DOI: 10.1007/s00125-004-1389-4
Portal and peripheral cortisol levels in obese humans
Abstract
Aims/hypothesis: Excess total body and visceral fat has been associated with insulin resistance, diabetes and the metabolic syndrome. Excess glucocorticoids produce both central obesity and diabetes. However, systemic glucocorticoid levels are normal in typical Type 2 diabetes and persons with idiopathic obesity. Glucocorticoids can be produced locally through the enzyme 11 beta hydroxysteroid dehydrogenase type 1 (11 beta HSD-1). Transgenic mice with selective overexpression in adipose tissue of 11 beta HSD-1 to levels seen in humans develop visceral obesity, hyperlipidaemia and insulin-resistant diabetes associated with a 2.7-fold increase in corticosterone levels in portal compared to peripheral circulation. To examine whether the liver is exposed to higher levels of glucocorticoids, which may undergo metabolic degradation prior to measurement in the systemic circulation, we assessed concentrations of cortisol in the portal and peripheral circulation in morbidly obese humans.
Methods: Portal and peripheral blood samples were obtained simultaneously from six morbidly obese humans with and without diabetes during bariatric abdominal surgery. The samples were assessed for serum cortisol to determine whether an increase in the portal to peripheral circulation is found in obese humans. Insulin, which undergoes metabolic clearance in the liver, and thyroxin (free T(4)), which does not, were also assessed.
Results: Levels of serum cortisol (698.8+/-200.4 vs 696.3+/-232.4 nmol/l, portal vs peripheral, p=0.9) and free T(4) (22.0+/-7.8 vs 20.6+/-8.1 pmol/l, portal vs peripheral, p=0.3) were not significantly different in portal compared to peripheral circulation. Portal insulins were significantly higher than peripheral levels (466.7+/-302.9 vs 78.5+/-50.9 pmol/l, portal vs peripheral, p=0.03).
Conclusions/interpretation: These observations suggest that in morbidly obese humans the liver is not exposed to excess glucocorticoids.
Comment in
-
Is "Cushing's disease of the omentum" an affliction of mouse and men?Diabetologia. 2004 May;47(5):767-9. doi: 10.1007/s00125-004-1390-y. Epub 2004 Apr 17. Diabetologia. 2004. PMID: 15095042 Review. No abstract available.
Similar articles
-
11beta-hydroxysteroid dehydrogenase type 1 and obesity.Front Horm Res. 2008;36:146-164. doi: 10.1159/000115363. Front Horm Res. 2008. PMID: 18230901 Review.
-
Portal and systemic levels of visfatin in morbidly obese subjects undergoing bariatric surgery.Endocrine. 2013 Aug;44(1):114-8. doi: 10.1007/s12020-012-9821-x. Epub 2012 Oct 28. Endocrine. 2013. PMID: 23104149 Clinical Trial.
-
Overexpression of 11β-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue and portal hypercortisolism in non-alcoholic fatty liver disease.Liver Int. 2012 Mar;32(3):392-9. doi: 10.1111/j.1478-3231.2011.02685.x. Epub 2011 Dec 4. Liver Int. 2012. PMID: 22136330
-
Overexpression of hepatic 5α-reductase and 11β-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue is associated with hyperinsulinemia in morbidly obese patients.Metabolism. 2011 Dec;60(12):1775-80. doi: 10.1016/j.metabol.2011.05.001. Epub 2011 Jun 24. Metabolism. 2011. PMID: 21704348
-
Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.Curr Drug Targets Immune Endocr Metabol Disord. 2003 Dec;3(4):255-62. doi: 10.2174/1568008033340135. Curr Drug Targets Immune Endocr Metabol Disord. 2003. PMID: 14683456 Review.
Cited by
-
Cortisol clearance and associations with insulin sensitivity, body fat and fatty liver in middle-aged men.Diabetologia. 2007 May;50(5):1024-32. doi: 10.1007/s00125-007-0629-9. Epub 2007 Mar 17. Diabetologia. 2007. PMID: 17370058
-
Translating PUFA omega 6:3 ratios from wild to captive hibernators (Urocitellus parryii) enhances sex-dependent mass-gain without increasing physiological stress indicators.J Comp Physiol B. 2022 Jul;192(3-4):529-540. doi: 10.1007/s00360-022-01437-6. Epub 2022 May 3. J Comp Physiol B. 2022. PMID: 35503574 Free PMC article.
-
Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 in obesity.Endocrine. 2006 Feb;29(1):101-8. doi: 10.1385/ENDO:29:1:101. Endocrine. 2006. PMID: 16622297 Review.
-
Cortisol release from adipose tissue by 11beta-hydroxysteroid dehydrogenase type 1 in humans.Diabetes. 2009 Jan;58(1):46-53. doi: 10.2337/db08-0969. Epub 2008 Oct 13. Diabetes. 2009. PMID: 18852329 Free PMC article. Clinical Trial.
-
Is "Cushing's disease of the omentum" an affliction of mouse and men?Diabetologia. 2004 May;47(5):767-9. doi: 10.1007/s00125-004-1390-y. Epub 2004 Apr 17. Diabetologia. 2004. PMID: 15095042 Review. No abstract available.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical